Withdrawn as Duplicate: The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin

Zasowski, Evan J; Trinh, Trang D; Atwan, Safana M; Merzlyakova, Marina; Langf, Abdalhamid M; Bhatia, Sahil; Rybak, Michael J.

doi:10.1093/ofid/ofz077

Cited by 10 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the combination therapy group, the median duration of vancomycin received was 5 days (interquartile range [IQR] 4–9 days) and the median duration for cefepime was 3 days (IQR 2–4 days); those in the monotherapy group received a median of 6 days of vancomycin (IQR 4–10 days). There was no difference in nephrotoxicity between the two groups (5.2% vs. 5.4%, P = 0.940) 30 .…”

Section: Vancomycin Combination Therapymentioning

confidence: 75%

“…Two recent retrospective cohort studies support the idea that other beta-lactams when used in combination with vancomycin may lead to less nephrotoxicity 30 , 31 . In one such study of adults with MRSA bacteremia, Zasowski et al .…”

Section: Vancomycin Combination Therapymentioning

confidence: 93%

“…In one such study of adults with MRSA bacteremia, Zasowski et al . compared 129 patients who received vancomycin alone with 229 patients who received vancomycin and cefepime (the latter had to be administered within 72 hours of starting vancomycin and for at least 24 hours) 30 . In the combination therapy group, the median duration of vancomycin received was 5 days (interquartile range [IQR] 4–9 days) and the median duration for cefepime was 3 days (IQR 2–4 days); those in the monotherapy group received a median of 6 days of vancomycin (IQR 4–10 days).…”

Section: Vancomycin Combination Therapymentioning

confidence: 99%

“…Multiple retrospective studies were included in a recent meta-analysis of 1636 patients from nine studies (four are reviewed in this article 30 – 33 ) that compared MRSA bacteremia or endocarditis patients who received vancomycin or daptomycin monotherapy with those who received either drug in combination with a beta-lactam 46 . Clinical failure rates were significantly lower in those who received combination therapy compared with monotherapy (odds ratio [OR] 0.56, CI 0.39–0.79; P <0.01) with lower rates of bacteremia relapse (OR 0.63, CI 0.43–0.92; P = 0.02) and persistent bacteremia (OR 0.56, CI 0.43–0.75; P = 0.01).…”

Section: Daptomycin Combination Therapymentioning

confidence: 99%

See 3 more Smart Citations

Select controversies in the management of methicillin-resistant Staphylococcus aureus bacteremia: answers and remaining questions from recent evidence

Suárez¹,

Onguti²,

Holubar³

2021

Fac Rev

View full text Add to dashboard Cite

Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia continues to cause significant morbidity and mortality despite advances in medical therapy. Vancomycin therapy remains the standard of care for most cases of MRSA bacteremia but has pharmacokinetic and pharmacodynamic limitations, dosing complications, and known toxicity. Welcomed clinical trials have recently addressed some of the controversies that plague this field, including optimization of vancomycin dosing and use of combination therapy. In this review, we discuss these trials and their implications for clinical care and future research.

show abstract

Section: Vancomycin Combination Therapymentioning

confidence: 75%

Section: Vancomycin Combination Therapymentioning

confidence: 93%

Section: Vancomycin Combination Therapymentioning

confidence: 99%

Section: Daptomycin Combination Therapymentioning

confidence: 99%

See 2 more Smart Citations

Select controversies in the management of methicillin-resistant Staphylococcus aureus bacteremia: answers and remaining questions from recent evidence

Suárez¹,

Onguti²,

Holubar³

2021

Fac Rev

View full text Add to dashboard Cite

show abstract

Monotherapy with Vancomycin or Daptomycin versus Combination Therapy with β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus Aureus Bloodstream Infections: A Retrospective Cohort Analysis

et al. 2020

View full text Add to dashboard Cite

Background: Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI) are associated with high morbidity and mortality. More in vitro, in vivo, and clinical data suggest that vancomycin (VAN) or daptomycin (DAP) combination therapy with b-lactams (BL) improves outcomes of MRSA infections. We hypothesize that BL combination with VAN or DAP would reduce the odds of clinical failure compared to VAN or DAP monotherapy. Methods: A retrospective cohort study of adult patients C 18 years treated with VAN or DAP for MRSA BSI from 2006 to 2019 at Detroit Medical Center. Combination therapy (CT) was defined as VAN or DAP plus any BL for C 24 h within 72 h of index culture. Monotherapy (MT) was defined as C 72 h VAN or DAP within 72 h of index culture and no BL for C 24 h up to 7 days following VAN/DAP initiation. Primary outcome was composite endpoint of clinical failure defined as: (1) 30-day mortality, (2) 60-day recurrence, or (3) persistent bacteremia (PB). PB was defined as bacteremia [ 5 days. Multivariable logistic regression was used to evaluate the association between CT and the primary outcome. Results: Overall, 597 patients were included in this analysis, 153 in the MT group and 444 in the CT group. CT was independently associated with reduced odds of clinical failure (adjusted odds ratio, 0.523; 95% confidence interval, 0.348-0.787). The composite endpoint was Enhanced Digital Features To view digital features for this article go to https://doi.org/10.6084/m9.figshare. 11973288.

show abstract

The Effect of Combination Therapy on Mortality and Adverse Events in Patients with Staphylococcus aureus Bacteraemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Wang

et al. 2021

Infect Dis Ther

View full text Add to dashboard Cite

Introduction: The findings of randomized controlled trials (RCTs), observational studies, and meta-analyses vary regarding the effectiveness and safety of combination therapy for patients with Staphylococcus aureus bacteraemia (SAB). We aimed to identify the effectiveness and safety of combination therapy in patients with SAB compared with those of monotherapy.Methods: We performed a systematic review and meta-analysis to compare combination therapy versus monotherapy in patients with SAB. Two authors independently searched PubMed, Embase, and the Cochrane Library of clinical trials until 17 February 2021. Any RCT comparing mortality or adverse events (AEs) of combination therapy versus monotherapy for patients with SAB was eligible. Summary risk ratios (RRs) and 95% confidence intervals (CIs) were evaluated using a random-effects model. The primary outcome was all-cause mortality at any time point. This meta-analysis is registered with the PROSPERO database (CRD42020188176) and reported according to PRISMA guidelines. Results: In total, 1906 articles were identified and screened, and 14 studies (2367 patients) Chao Ye and Chunjiang Wang contributed equally to this paper.

show abstract

Withdrawn as Duplicate: The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin

Cited by 10 publications

References 0 publications

Select controversies in the management of methicillin-resistant Staphylococcus aureus bacteremia: answers and remaining questions from recent evidence

Select controversies in the management of methicillin-resistant Staphylococcus aureus bacteremia: answers and remaining questions from recent evidence

Monotherapy with Vancomycin or Daptomycin versus Combination Therapy with β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus Aureus Bloodstream Infections: A Retrospective Cohort Analysis

The Effect of Combination Therapy on Mortality and Adverse Events in Patients with Staphylococcus aureus Bacteraemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Contact Info

Product

Resources

About